News

Fierce Pharma8h

Enhertu, Keytruda promos put AZ, Merck at the front of the oncology HCP marketing pack: report

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...
Zacks Investment Research on MSN11h

Exelixis Gains 15.6% YTD: How Should You Play the Stock?

Exelixis’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the ...